Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Oncology | Hematology
Cutaneous T-Cell Lymphoma Clinical Trials
A listing of Cutaneous T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama - Birmingham
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
California
Stanford : Stanford Cancer Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Stanford : Stanford University School of Medicine
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Stanford : Stanford Medical Center
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Illinois
Chicago : Northwestern Memorial Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Massachusetts
Boston : Boston University Medical Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Boston : Boston Medical Center
Everolimus in Treating Cutaneous T-cell Lymphoma
Missouri
St. Louis : Washington University School of Medicine
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
New Jersey
Hackensack : John Theurer Cancer Center (Hackensack University Medical Center)
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
New York
New York : Memorial Sloan-Kettering Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Rochester : University of Rochester School of Medicine
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Pennsylvania
Philadelphia : Fox Chase Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Pittsburgh : University of Pittsburgh
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Pittsburgh : University of Pittsburgh School of Medicine
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Texas
Houston : MD Anderson Cancer Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Houston : MD Anderson Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Australia
Concord : Concord Repatriation General Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
East Melbourne : Peter MacCallum Cancer Centre
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Nedlands : Sir Charles Gairdner Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Belgium
Leuven : UZ Leuven
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Germany
Kiel : Klinik für Dermatologie, Venerologie und Allergologie
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Italy
Bologna : A.O.U. Policlinico S.Orsola Malpighi
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Bologna : Ospedale Sant'Orsola - Policlinico Sant'Orsola
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Spain
Madrid : Hospital Universitario 12 de Octubre
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
United Kingdom
Leeds : St. James University Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
London : St. John's Institute of Dermatology
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Manchester : Manchester Cancer Research Centre
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
